DT Investment Partners LLC Sells 65 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DT Investment Partners LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 51.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 62 shares of the company’s stock after selling 65 shares during the period. DT Investment Partners LLC’s holdings in IDEXX Laboratories were worth $26,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in IDXX. Creative Planning increased its position in IDEXX Laboratories by 2.6% in the 3rd quarter. Creative Planning now owns 24,436 shares of the company’s stock worth $12,346,000 after buying an additional 614 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in IDEXX Laboratories by 19.0% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 3,306 shares of the company’s stock worth $1,670,000 after buying an additional 529 shares during the period. Bleakley Financial Group LLC increased its position in IDEXX Laboratories by 1.4% in the 3rd quarter. Bleakley Financial Group LLC now owns 2,861 shares of the company’s stock worth $1,445,000 after buying an additional 39 shares during the period. Marshall Financial Group LLC increased its position in IDEXX Laboratories by 1.6% in the 3rd quarter. Marshall Financial Group LLC now owns 1,884 shares of the company’s stock worth $952,000 after buying an additional 30 shares during the period. Finally, Cardinal Capital Management increased its position in IDEXX Laboratories by 0.7% in the 3rd quarter. Cardinal Capital Management now owns 13,919 shares of the company’s stock worth $7,032,000 after buying an additional 93 shares during the period. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock worth $6,161,276 over the last 90 days. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $444.53 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock’s 50 day moving average price is $430.77 and its two-hundred day moving average price is $453.31. The firm has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.